These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. The baculovirus expression vector system: a modern technology for the future of influenza vaccine manufacturing. Trombetta CM; Marchi S; Montomoli E Expert Rev Vaccines; 2022 Sep; 21(9):1233-1242. PubMed ID: 35678205 [TBL] [Abstract][Full Text] [Related]
25. Current Status and Future Perspectives on MRNA Drug Manufacturing. Webb C; Ip S; Bathula NV; Popova P; Soriano SKV; Ly HH; Eryilmaz B; Nguyen Huu VA; Broadhead R; Rabel M; Villamagna I; Abraham S; Raeesi V; Thomas A; Clarke S; Ramsay EC; Perrie Y; Blakney AK Mol Pharm; 2022 Apr; 19(4):1047-1058. PubMed ID: 35238565 [TBL] [Abstract][Full Text] [Related]
26. Sustainable vaccine manufacturing in low- and middle-Income countries. Hayman B; Kumar Suri R; Downham M Vaccine; 2022 Nov; 40(50):7288-7304. PubMed ID: 36334966 [TBL] [Abstract][Full Text] [Related]
27. Real-world effectiveness of the inactivated COVID-19 vaccines against variant of concerns: meta-analysis. Sarwar MU; Waasia FZ; Aloqbi AA; Alandiyjany M; Alqahtani RM; Hafiz LA; Shamlan G; Albreiki M J Infect Public Health; 2024 Feb; 17(2):245-253. PubMed ID: 38141544 [TBL] [Abstract][Full Text] [Related]
28. A systems immunology study comparing innate and adaptive immune responses in adults to COVID-19 mRNA and adenovirus vectored vaccines. Ryan FJ; Norton TS; McCafferty C; Blake SJ; Stevens NE; James J; Eden GL; Tee YC; Benson SC; Masavuli MG; Yeow AEL; Abayasingam A; Agapiou D; Stevens H; Zecha J; Messina NL; Curtis N; Ignjatovic V; Monagle P; Tran H; McFadyen JD; Bull RA; Grubor-Bauk B; Lynn MA; Botten R; Barry SE; Lynn DJ Cell Rep Med; 2023 Mar; 4(3):100971. PubMed ID: 36871558 [TBL] [Abstract][Full Text] [Related]
29. Vaccine complacency and dose distribution inequities limit the benefits of seasonal influenza vaccination, despite a positive trend in use. Palache A; Rockman S; Taylor B; Akcay M; Billington JK; Barbosa P; Vaccine; 2021 Oct; 39(41):6081-6087. PubMed ID: 34521551 [TBL] [Abstract][Full Text] [Related]
30. The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. Machado BAS; Hodel KVS; Fonseca LMDS; Mascarenhas LAB; Andrade LPCDS; Rocha VPC; Soares MBP; Berglund P; Duthie MS; Reed SG; Badaró R Vaccines (Basel); 2021 Nov; 9(11):. PubMed ID: 34835276 [TBL] [Abstract][Full Text] [Related]
31. A Cross-sectional Survey of Public Knowledge and Perspective on Coronavirus Disease, Vaccination, and Related Research in India during the COVID-19 Pandemic. Munshi R; Maurya M J Assoc Physicians India; 2023 Sep; 71(9):19-27. PubMed ID: 38700297 [TBL] [Abstract][Full Text] [Related]
32. Pivoting to protein: the immunogenicity and safety of protein-based NVX-CoV2373 as a heterologous booster for inactivated and viral vector COVID-19 vaccines. Marchese AM; Kalkeri R; Vadivale M; Suntronwong N; Toback S; Poovorawan Y Expert Rev Vaccines; 2023; 22(1):620-628. PubMed ID: 37386785 [TBL] [Abstract][Full Text] [Related]
33. Interchangeability of different COVID-19 vaccine platforms as booster doses: A phase 3 study mimicking real-world practice. Ann Costa Clemens S; Weckx L; Milan EP; Smolenov I; Clemens R Vaccine; 2024 Jul; 42(19):3989-3998. PubMed ID: 38762360 [TBL] [Abstract][Full Text] [Related]
34. Global pandemic preparedness: learning from the COVID-19 vaccine development and distribution. Agampodi S; Mogeni OD; Chandler R; Pansuriya M; Kim JH; Excler JL Expert Rev Vaccines; 2024; 23(1):761-772. PubMed ID: 39167221 [TBL] [Abstract][Full Text] [Related]